HIV Gene Therapy

Recombinant AAV-2 with gfp-Antisense Has Anti-HIV-1 Effect

Published in Gene Therapy Weekly, August 9th, 1999

A recombinant adeno-associated virus type 2 (AAV-2) harboring a green fluorescent protein (GFP)-antisense/ribozyme fusion sequences has anti-HIV-1 efficacy.

A. Horster and colleagues from the Deutsches Krebsforschungszentrum, Germany, suggested that vector-mediated delivery of potentially antivirally active genes is a key step in somatic gene therapy against AIDS ("Recombinant AAV-2 Harboring gfp-Antisense/Ribozyme Fusion Sequences Monitor Transduction, Gene Expression, and Show Anti-HIV-1 Efficacy," Gene Therapy, July 1999;6(7):1231-38).

"In order to provide a tool to study transduction of primary target cells for an anti-HIV gene therapy and to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1999-08-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry